M. Wiesel

发表

DNA amplification of HIV genome in hemophiliacs and in newborns from seropositive mothers

J. Cazenave, P. Lutz, B. Guy, 1991, Annals of Hematology.

Long-Chain n-3 Fatty Acids Specifically Affect Rat Coagulation Factors Dependent on Vitamin K: Relation to Peroxidative Stress

M. Freund, J. Cazenave, C. Gachet, 2001, Arteriosclerosis, thrombosis, and vascular biology.

Von Willebrand factor in diabetic angiopathy.

J. Cazenave, M. Pinget, L. Kessler, 1998, Diabetes & metabolism.

A new recombinant procoagulant protein derived from the cDNA encoding human factor VIII.

T. Faure, C. Mazurier, P. Meulien, 1988, Protein engineering.

Evaluation of soluble glycoprotein V as a marker of venous thromboembolism

J. Cazenave, C. Gachet, T. Kirchgesner, 2011, Thrombosis and Haemostasis.

Variation in von Willebrand's Factor according to the treatment of acute myocardial infarction: physiopathological and clinical implications.

J. Cazenave, R. Arbogast, G. Roul, 1994, European heart journal.

Potential thrombogenicity of coronary angioplasty compared with coronary angiography.

J. Cazenave, R. Arbogast, G. Roul, 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Hemostatic properties and protein expression profile of therapeutic apheresis plasma treated with amotosalen and ultraviolet A for pathogen inactivation

J. Cazenave, C. Gachet, P. Ohlmann, 2016, Transfusion.

Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers

T. Hervig, J. Cazenave, L. Corash, 2008, Transfusion.

Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin®) in the prophylaxis of thromboembolic complications of abdominal oncological surgery

J. Fricker, J. Cazenave, M. Wiesel, 1988, European journal of clinical investigation.

Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3‐year period

J. Cazenave, L. Corash, M. Wiesel, 2011, Transfusion.

Significance of Diminished Factor XIII in Crohn's Disease

R. Baumann, J. Sibilia, J. Cazenave, 1998 .

Significance of Diminished Factor XIII in Crohn's Disease

R. Baumann, J. Sibilia, J. Cazenave, 1998, American Journal of Gastroenterology.

Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.

O. Morel, P. Ohlmann, C. Gachet, 2010, JACC. Cardiovascular interventions.

In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set

J. Cazenave, B. Aleil, M. Wiesel, 2006, Vox sanguinis.

Diets enriched in (n-3) fatty acids affect rat coagulation factors dependent on vitamin K.

M. Freund, J. Cazenave, C. Gachet, 1998, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

Artifact of blood pressure recording using heparin-filled catheter: effects on blood pressure and coagulation parameters.

M. Wiesel, A. Beretz, V. Martin, 1996, Journal of pharmacological and toxicological methods.

The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: Roles of white blood cell count and body weight

O. Morel, S. Hess, P. Ohlmann, 2012, Thrombosis and Haemostasis.

Soluble Platelet Glycoprotein V Is a Marker of Thrombosis in Patients With Ischemic Stroke

M. Giroud, J. Cazenave, V. Wolff, 2005, Stroke.

One-step assay for the determination of free protein S antigen in plasma using real-time biospecific interaction analysis.

J. Cazenave, J. Amiral, C. Ravanat, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

An IgM Lupus Anticoagulant that Neutralizes the Enhancing Effect of Phospholipid on Purified Endothelial Thrombomodulin Activity-A Mechanism for Thrombosis

J. Freyssinet, J. Cazenave, B. Boneu, 1986, Thrombosis and Haemostasis.

Choosing a Host Cell for Active Recombinant Factor VIII Production Using Vaccinia Virus

J. Cazenave, A. Pavirani, J. Lecocq, 1987, Bio/Technology.

Large scale isolation of human blood monocytes by continuous flow centrifugation leukapheresis and counterflow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients.

J. Bergerat, S. Dumont, A. Bohbot, 1994, Journal of immunological methods.

Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.

O. Morel, P. Ohlmann, C. Gachet, 2011, Atherosclerosis.

Potential thrombogenicity of angiographic contrast agents.

J. Cazenave, M. Wiesel, L. Grunebaum, 1991, Thrombosis research.

Prothrombin fragment 1+2 and thrombin–antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases

M. Wiesel, L. Grunebaum, J. Cazenave, 1995, European journal of gastroenterology & hepatology.

Nucleotide metabolism and ADPase activity in cardiac and renal transplantation.

J. Cazenave, C. Gachet, B. Moulin, 2000, Transplantation proceedings.

Effects of clopidogrel and its inactive form, SR 25989, on plasma, liver and platelet lipids in the rat.

M. Freund, J. Cazenave, C. Gachet, 1998, Platelets.

Sensitivity and long‐term prognostic value of cardiac troponin‐i increase shortly after percutaneous transluminal coronary angioplasty

J. Cazenave, J. Mossard, B. Aleil, 1998, Clinical cardiology.

Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: Toxicity and immunomodulatory effects

P. Poindron, S. Dumont, A. Bohbot, 2005, Cancer Immunology, Immunotherapy.

Antiphospholipid antibodies in inflammatory bowel disease

J. Freyssinet, R. Baumann, J. Fontcuberta, 1995, Digestive Diseases and Sciences.

Apheresis-Elutriation Program for Adoptive Immunotherapy with Autologous Activated Monocytes in Cancer Patients

J. Bergerat, P. Poindron, S. Dumont, 1991, The International journal of artificial organs.

[Preliminary results of a randomized trial comparing the efficacy of standard heparin with that of fragmine, a low molecular weight heparin, in the prevention of postoperative thrombosis in cancer surgery].

J. Fricker, J. Cazenave, M. Wiesel, 1987, Journal des maladies vasculaires.

Plasma glycoprotein V levels in the general population: Normal distribution, associated parameters and implications for clinical studies

J. Cazenave, C. Gachet, V. Wolff, 2006, Thrombosis and Haemostasis.

Potential role of von Willebrand factor in pancreatic venous thrombosis in simultaneous kidney and pancreas transplantation.

K. Boudjema, J. Cazenave, M. Pinget, 1997, Transplantation proceedings.

Two independent domains of factor VIII co-expressed using recombinant vaccinia viruses have procoagulant activity.

J. Cazenave, A. Pavirani, J. Lecocq, 1987, Biochemical and biophysical research communications.

Between light and dark, the chimera comes out.

D. Lipsker, H. de la Salle, D. Hanau, 2008, Archives of dermatology.

Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel.

O. Morel, P. Ohlmann, C. Gachet, 2011, Journal of the American College of Cardiology.

[Serum cardiolipin antibodies in patients with alcoholic cirrhosis].

J. Cazenave, A. Aupérin, A. Gervais, 1996, Gastroentérologie Clinique et Biologique.

Novel point mutations leading to type 1 antithrombin deficiency and thrombosis

G. Leone, S. Thein, J. Cazenave, 1991, British journal of haematology.

Carrier detection in hemophilia using pedigree analysis coagulation tests and DNA probes.

J. Cazenave, A. Blanco, M. Baas, 1989, Nouvelle revue francaise d'hematologie.

Arterial Thrombosis and Protein S Deficiency

J. Cazenave, B. Boneu, M. Wiesel, 1989, Thrombosis and Haemostasis.

Phase I study of liposomal MTP-PE-activated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis.

J. Bergerat, A. Bohbot, P. Dufour, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hemostatic changes in human adoptive immunotherapy with activated blood monocytes or derived macrophages

J. Bergerat, J. Cazenave, A. Bohbot, 1992, Annals of Hematology.

Clinical Experience with Pathogen Inactivation of Platelet Components for Transfusion Support

J. Cazenave, M. Wiesel, C. Waller, 2008 .

A Randomized Study of On-Line Plasma Perfusion over Protein A-Sepharose and 5-Fluorouracil Chemotherapy in Patients with Metastatic Colorectal Carcinoma

J. Bergerat, J. Cazenave, A. Bohbot, 1991, The International journal of artificial organs.

Adrenaline Activates Human Platelets But Does Not Cause Primary Aggregation If Thrombin Generation Is Inhibited By Hirudin

J. Cazenave, A. Sutter, M. Wiesel, 1981, Thrombosis and Haemostasis.

Increased plasma levels of soluble platelet glycoprotein V in patients with acute myocardial infarction

J. Mossard, B. Aleil, F. Lanza, 2003, Journal of thrombosis and haemostasis : JTH.

Electrophoretic studies on molecular defects of von Willebrand factor and platelet glycoprotein IIb-IIIa with antibodies produced in egg yolk from laying hens.

P. Ohlmann, J. Cazenave, C. Gachet, 1992, Haemostasis.

A Deletion Located in the 3′ Non Translated Part of the Factor IX Gene Responsible for Mild Haemophilia B

M. Baas, M. Wiesel, L. Grunebaum, 1993, Thrombosis and Haemostasis.

Possible involvement of Von Willebrand factor in pancreatic graft thrombosis after kidney-pancreas transplantation: a retrospective study.

K. Boudjema, J. Cazenave, M. Pinget, 1998, Clinical transplantation.

Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link?

J. Cazenave, T. Hannedouche, B. Moulin, 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Activation of human protein C by blood coagulation factor Xa in the presence of anionic phospholipids. Enhancement by sulphated polysaccharides.

J. Freyssinet, G. Freund, J. Cazenave, 1989, The Biochemical journal.

Screening of protein S deficiency using a functional assay in patients with venous and arterial thrombosis.

J. Freyssinet, J. Cazenave, M. Wiesel, 1990, Thrombosis research.

Prevalence and significance of anticardiolipin antibodies in Crohn's disease

J. Freyssinet, R. Baumann, J. Cazenave, 1994, Digestive Diseases and Sciences.

Anticorps antiphospholipides (aPL): détection et signification clinique

M. Wiesel, J. Goetz, M. Imler, 1992 .

Depression and anxiety in elderly patients with severe symptomatic aortic stenosis persistently improves after transcatheter aortic valve replacement (TAVR).

P. Schulze, S. Möbius‐Winkler, G. Dannberg, 2020, International journal of cardiology.

Biological and clinical heterogeneity of lupus and lupus-like anticoagulant in fifty-seven patients.

M. Samama, M. Horellou, M. Boffa, 1988, Journal of medicine.

Antiphospholipid Antibodies and Preeclampsia: A Case‐Control Study

G. Hédelin, M. Dreyfus, B. Viville, 2001, Obstetrics and gynecology.

[Influence of protein S deficiency on the arterial thrombosis risk].

H. Lévesque, J. Borg, M. Vasse, 1991, Presse medicale.

Effects of cerivastatin on lipid profiles, lipid peroxidation and platelet and endothelial activation in renal transplant recipients.

J. Cazenave, C. Gachet, B. Moulin, 2000, Transplantation proceedings.

Pyridoxal Phosphate (PALP) Inhibits Three Major Steps Involved in Thrombus Formation : Adhesion to Collagen, Aggregation by Adp and the Effects of Thrombin on Human Platelets

M. Wiesel, S. Hemmendinger, A. Beretz, 1983 .

The treatment of deep vein thrombosis with continuous intravenous low-molecular-weight dermatan sulphate (Desmin). A pilot study.

J. Cazenave, N. Chakfé, E. Palazzini, 1996, Thrombosis research.

Plasma levels of soluble platelet glycoprotein V are linked to fasting blood glucose in patients with type 2 diabetes

J. Cazenave, C. Gachet, M. Pinget, 2008, Thrombosis and Haemostasis.

Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates.

J. Cazenave, B. Boneu, Y. Sultan, 1988, Nouvelle revue francaise d'hematologie.

Production of an Antibody Against Human Protein C and its Use to Detect Patients with Congenital Protein C Deficiency Associated with Thrombosis

J. Freyssinet, J. Cazenave, R. Fritsché, 1985 .

In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using amotosalen

J. Cazenave, B. Aleil, M. Wiesel, 2004, Vox Sanguinis.

Hairy cell leukemia and factor VIII inhibitor: a case report.

J. Bergerat, F. Oberling, P. Dufour, 1992, Nouvelle revue francaise d'hematologie.

A randomized study of combined 5-fluorouracil and plasma perfusion over protein A-Sepharose in human advanced colorectal carcinoma

J. Bergerat, J. Cazenave, A. Bohbot, 1990, Biotherapy.